A Clinical Study of Raludotatug Deruxtecan in People with Ovarian Cancer (MK-5909-003)

Trial Identifier: 5909-003
Sponsor: MSD
Collaborator:
Daiichi Sankyo, Inc.
Start Date: April 2025
Primary Completion Date: March 2029
Study Completion Date: March 2029
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9103102
Israel, N/A Petah Tikva, N/A, Israel, 4941492
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Spain, Barcelona Barcelona, Spain, 08035
Spain, Barcelona L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Spain, Madrid Madrid, Spain, 28041
Spain, Madrid Madrid, Spain, 28040
Spain, Madrid Majadhonda, Madrid, Spain, 28222
Spain, Madrid, Comunidad de Madrid, Madrid, Comunidad de, Spain, 28027
Spain, Malaga Malaga, Spain, 29010
Spain, Valenciana, Comunitat Valencia, Valenciana, Comunitat, Spain, 46014
United Kingdom, East Sussex Brighton, East Sussex, United Kingdom, BN2 1ES
United Kingdom, England Fulham, England, United Kingdom, SW3 6JJ
United Kingdom, England Sutton, England, United Kingdom, SM2 5PT
United Kingdom, London, City of London, London, City of, United Kingdom, E1 1RD
United Kingdom, Manchester Manchester, United Kingdom, M20 4BX
United States, CT New Haven, CT, United States, 06510
United States, KY Louisville, KY, United States, 40202
United States, MA Boston, MA, United States, 02215
United States, NY New York, NY, United States, 10065
United States, OK Oklahoma City, OK, United States, 73104
United States, TX Fort Worth, TX, United States, 76104
United States, TX Houston, TX, United States, 77030
United States, UT West Valley City, UT, United States, 84119
United States, VA Charlottesville, VA, United States, 22908